BeyondSpring (BYSI) Income from Discontinued Operations (2024 - 2025)
BeyondSpring (BYSI) posted Income from Discontinued Operations of 12488000.0 for Q3 2025, down 59.53% sequentially from 7828000.0 in Q3 2024, and down 59.53% YoY from 30857343.43 in Q3 2024.
BeyondSpring (BYSI) Income from Discontinued Operations (2024 - 2025) Analysis & Trends
BeyondSpring has reported Income from Discontinued Operations for 2 years, with the latest figure at 12488000.0 in Q3 2025.
- Quarterly Income from Discontinued Operations fell 59.53% year-over-year to 12488000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 12488000.0 (down 59.53% YoY) and the FY2023 annual result came in at 14000.0, changed N/A from the prior year.
- Income from Discontinued Operations slipped to 12488000.0 in Q3 2025 per BYSI's latest filing, from 7828000.0 in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at 7828000.0 in Q3 2024 and troughed at 12488000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | -3.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -12.49 Mn |
| Sep 30, 2024 | -7.83 Mn |